Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEC-162 on Circadian Rhythm in Healthy Subjects
NCT00490945Phase 2Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jul 2004
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in circadian rhythm sleep disorders (CRSD) comparing VEC-162 with Placebo (2 arms). Primary endpoints: Circadian Phase Shift and Mean Sleep Efficiency. Started Jul 2004; status: completed.
02
Drugs
tasimelteon
03
Conditions
circadian rhythm sleep disorders (CRSD)
Beyond the preview
Go deeper on NCT00490945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490945.